Dennis Gable (The Heart Hospital Baylor Plano, Plano, Texas), principal investigator for the thoracic component of the GREAT registry, explains that this is a real-world evaluation of use of WL Gore’s aortic products in the abdomen and in the thoracic aorta. The multicenter dataset drew from 113 centers, over 14 countries and four continents.
Speaking on the subset of 578 patients, who were “all comers” that have thoracic pathology, including aneurysmal disease, dissection, intramural hematoma or aortic penetrating ulcer, Gable said: “We had a follow-up of over 95% in general for all patients. This is now providing the long-term follow-up that we did not have before.”
Further key highlights from the dataset were findings such as the overall rate of freedom from aortic-related mortality of just under 95% and an all-cause mortality of just over 66%. Gable noted: “Fortunately [these patients] are not succumbing to issues related to their aorta after they’ve been treated with these devices.”
Analysis of the data on complications further showed very low rates of reintervention, spinal cord ischemia and low rates of stroke. All this, despite the fact that nearly 44% of all patients were treated off-label, emphasised Gable.
This video was sponsored by W.L. Gore & Associates.
